An innovative service company focusing on the field of drug quality control

News

Contact Us

You are here:Home >> News >> Company News

Company News

Fenofibrate Impurities - SZEB

Time:2023-05-06 Views:138
Fenofibrate is FDA approved to treat patients with hypertriglyceridemia, primary hypercholesterolemia, or mixed dyslipidemia. It reduces low-density lipoprotein cholesterol (LDL-C), total cholesterol, triglycerides, and apolipoprotein B and increases high-density lipoprotein cholesterol (HDL-C) in adults.
To support your analysis and help ensure the accuracy of quality processes, we supply a range of Fenofibrate -related impurities standards with certified COA and characterization data like Mass, HPLC, NMR & TGA report.
The following are some of the impurities of Fenofibrate :
  • Previous:zopiclone impurities|SZEB  2024/03/20
  • Next:Antipsychotics - Brexpiprazole  2023/04/28